Nsclc

D3 Bio’s First‑Line Data Shows Landmark Efficacy of Elisrasib in KRAS G12C‑Positive NSCLC

A Significant Setback: Arcus Biosciences Halts Key Lung Cancer Trial with Gilead

Summit Therapeutics on the Cusp: A Dual-Action Lung Cancer Drug Faces its Moment of Truth

ArriVent BioPharma: Decoding the 'Cautious Buy' on Furmonertinib

The High-Stakes Gamble: Summit's Vision vs. Akeso's Strategic Play with Ivonesimab

A Grand Promise, A Tricky Map: Navigating Cancer with Antibody-Drug Conjugates

A Shifting Tide: The Revolution in Lung Cancer Care

Breakthrough in Lung Cancer Treatment: Positive Phase 3 OPTITROP-Lung04 Trial Results for Sacituzumab Tirumotecan Unveiled

Cullinan Therapeutics' Breakthrough Cancer Drug Shows Remarkable Efficacy Against Brain Metastases in Lung Cancer Patients

A New Dawn in Lung Cancer Treatment: Gilead and Arcus's Investigational Therapy Shows Promising Survival Advantage

AstraZeneca's Revolutionary Lung Cancer Drug Receives Green Light in India

Summit Therapeutics' Lung Cancer Hope Faces Fierce Competition and Scrutiny

Summit Therapeutics Soars: Cancer Drug Ivonesimab Delivers Breakthrough Survival Gains, Igniting Retail Investor Frenzy

A New Horizon in Lung Cancer Treatment: FDA Grants Breakthrough Status to Lilly-Merck Combination Therapy

Groundbreaking Cancer Drug Ivonescimab Propels Akeso Shares After Major Clinical Trial Success